Browsing Tag
American Association for Cancer Research
11 posts
Rznomics gets FDA RMAT status for RZ-001, but can one liver cancer signal carry a platform story?
RNA editing has a regulatory opening in liver cancer. Rznomics now must prove RZ-001 can turn FDA momentum into durable clinical value.
What does Abbott’s Cancerguard AACR data mean for multi-cancer early detection and the $21bn Exact Sciences acquisition?
Abbott presents Cancerguard dual-biomarker MCED data at AACR 2026. What the DETECT-A survival findings mean for ABT, GRAIL, and cancer screening. Read more.
Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AACR 2026 with post-TKI ROS1 lung cancer data
Nuvalent’s AACR 2026 zidesamtinib data could reshape the ROS1 NSCLC treatment debate ahead of its FDA decision. Read what it means now.
Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
SK Life Science Labs unveiled new AACR 2026 preclinical data on p300 and PRMT5 degraders. Read why this oncology strategy could matter next.
AACR Annual Meeting 2026: what cancer researchers and pharma professionals need to know before San Diego
AACR Annual Meeting 2026 runs April 17-22 at San Diego Convention Center. Over 7,400 abstracts, six plenaries, AI, CAR T, ADCs and RAS inhibitor data.
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.
Senhwa Biosciences expands CX-5461 into photodynamic therapy as AACR 2026 spotlight raises strategic optionality
Senhwa Biosciences expands CX-5461 into photodynamic therapy. Discover how this dual-mechanism strategy could reshape oncology innovation today.
Antengene deepens oncology ambitions with three next-generation ADC and T-cell engager programs at AACR 2026
Discover how Antengene Corporation Limited’s AACR 2026 oncology presentations could reshape its pipeline strategy and investor outlook. Read the full analysis.
CStone Pharmaceuticals unveils next-generation ADC pipeline at AACR 2025 as it shifts to proprietary innovation model
CStone Pharmaceuticals reveals powerful preclinical ADC data at AACR 2025, fueling investor interest in its next-gen oncology pipeline and IND filing momentum.
Inocras launches MRDVision with ppm-level sensitivity, setting new standard in cancer recurrence detection
Inocras launches MRDVision with ppm-level ctDNA sensitivity, setting a new MRD testing standard—discover how it could transform cancer monitoring today.